Compare TBI & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TBI | TLSA |
|---|---|---|
| Founded | 1985 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 129.9M | 155.2M |
| IPO Year | 1995 | 2017 |
| Metric | TBI | TLSA |
|---|---|---|
| Price | $3.31 | $1.24 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | ★ 254.5K | 125.2K |
| Earning Date | 05-04-2026 | 05-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.39 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $6.25 | N/A |
| Revenue Next Year | $3.90 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.42 | $0.73 |
| 52 Week High | $7.78 | $2.60 |
| Indicator | TBI | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 30.38 | 46.09 |
| Support Level | N/A | $1.27 |
| Resistance Level | $5.56 | $1.59 |
| Average True Range (ATR) | 0.23 | 0.11 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 1.32 | 36.00 |
TrueBlue Inc is a provider of specialized workforce solutions that connect employers with talent. Its reportable segments include PeopleReady, which provides blue-collar contingent staffing and delivers on-demand and skilled labor across industries such as construction, transportation, retail, hospitality, and energy. The PeopleManagement segment offers contingent labor and outsourced industrial workforce solutions, mainly on-site at client facilities, through its OnSite and Centerline operations, focusing on workforce management and commercial driver services. PeopleSolutions delivers services focused on professional and specialized talent acquisition, as well as workforce management and compliance. The company generates the majority of its revenue from the PeopleReady segment.
Tiziana Life Sciences Ltd is a clinical stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Alzheimer's, and ALS. Its flagship immunotherapeutic candidate, Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody, is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's and other CNS indications.